Phase 2 Stroke Trial, Recruiting NCT06813651 Sponsor: ThromBio Pty. Ltd. Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT06813651
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have had an acute ischaemic stroke (a stroke caused by a blockage) involving two connected blockages — one in a blood vessel inside the brain and one in the main artery in the neck, where the neck blockage is thought to be caused by fatty buildup in the artery walls
  • People whose brain scan results show a meaningful amount of brain tissue that may still be saved, based on specific measurements of the affected area (confirm with trial site for exact scan thresholds)
  • People with at least a mild level of stroke-related neurological impairment, as measured by a standard medical scoring scale (confirm with trial site)
  • People who were largely independent in daily life before their stroke, based on a standard disability rating scale (confirm with trial site)

Who may not be able to join:

  • People considered unlikely to benefit from the study treatment, including those with advanced dementia, severe disability before their stroke, a very low level of consciousness, or a large area of already-damaged brain tissue
  • People with severely high blood pressure that has not responded to treatment
  • People who have had bleeding inside the brain within the last 90 days
  • People who have had a heart attack or stroke within the last 30 days
  • People with an existing illness where life expectancy is less than 90 days
  • People known to be taking blood-thinning (anticoagulant) medications
  • People with known severe liver disease
  • People with a known bleeding disorder
  • People who have had CPR, a needle inserted into a site where pressure cannot be applied to stop bleeding, or a lumbar puncture within the last 7 days
  • People with another medical condition or personal circumstance that may interfere with follow-up assessments
  • People who are known or suspected to be pregnant
  • People currently taking part in another interventional clinical trial
  • People for whom informed consent cannot be obtained from themselves or their authorised decision-maker before the study procedures begin

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ferdinand Miteff - Interventional Neurologist, RACP, CCINR, John Hunter Hospital, Newcastle, NSW Australia

Phone: 612 4921 3490

Australian sites

John Hunter Hospital, Newcastle, New South Wales
Royal North Shore Hospital, St Leonards, New South Wales
+61299267111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
ThromBio Pty. Ltd.
Registry
ClinicalTrials.gov
Start date
4 October 2025
Est. completion
30 December 2026

Where this trial is recruiting

🇦🇺 Australia

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Proportion of patients achieving a composite outcome of efficacy and safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov